All In Biotech

Free tool

FAERS Monitor: Betadine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018634 or its brand name (Betadine, Povidone-Iodine). Reports on generic versions are filed under their own applications.

Reports

3,733

Serious

3,018

81% of reports

Hospitalization

1,150

Death reported

423

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use472
  • endophthalmitis384
  • drug hypersensitivity375
  • drug ineffective306
  • rash277
  • toxic anterior segment syndrome235
  • nausea228
  • pain213
  • eye pain182
  • product use in unapproved indication176
  • vision blurred158
  • hypersensitivity154
  • dyspnoea153
  • confusional state151
  • rheumatoid arthritis143

Reports by year received

View as table
YearReports
200417
200511
200638
200713
200825
200936
201077
201129
2012129
2013142
2014203
2015141
2016230
2017335
2018315
2019359
2020203
2021176
2022259
2023178
2024250
2025317
2026250

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,426 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
toxic anterior segment syndromeSignal2351548.11344.9283,873
endophthalmitisSignal384385.2349.2137,431
eye painSignal18218.215.82,945
drug hypersensitivitySignal37510.99.93,401
rheumatoid arthritisSignal1437.16.0747
vision blurredSignal1586.55.6732
confusional stateSignal1515.34.5522
hypersensitivitySignal1544.74.0445
product use in unapproved indicationSignal1764.03.5398
rashSignal2773.63.2524
off label useSignal4723.02.8671
pain2132.01.7101
nausea2281.61.456
dyspnoea1531.51.328
drug ineffective3061.31.223

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.